Zynerba Pharmaceuticals (ZYNE) News and press releases

Zynerba Pharmaceuticals R&D Expenses For Q1 Reach $7.1M, Here Are The Details

15 May 23

Cannabis, Earnings, News, Penny Stocks, Markets

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) released financial results for the first quarter ended March 31, 2023, revealing research and development expenses were $7.1 million for the first quarter of 2023, including stock-based compensation of $400,000.

Zynerba Pharmaceuticals Q1 EPS $(0.21) Misses $(0.19) Estimate; $44.4M In Cash And Cash Equivalents, With Cash Runway To Mid-year 2024

15 May 23

Earnings, News

Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.19) by 10.53 percent. This is unchanged from the same period last year.

Stocks That Hit 52-Week Lows On Wednesday

26 Apr 23

Options

On Wednesday, 345 companies set new 52-week lows.

Zynerba Pharmaceuticals R&D Expenses For FY22 Reach $21.1M, What About Net Loss?

28 Mar 23

Cannabis, Earnings, News, Penny Stocks, Markets

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) released financial results for the fourth quarter and full year ended December 31, 2022, revealing research and development expenses were $21.1 million for full year 2022, including stock-based compensation of $2.0 million.

Zynerba Pharmaceuticals Q4 EPS $(0.18), Inline

28 Mar 23

Earnings, News

Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported quarterly losses of $(0.18) per share which met the analyst consensus estimate. This is a 18.18 percent increase over losses of $(0.22) per share from the same period last

Silicon Valley Bank Failure Is Just The Tip Of Financial Iceberg, Could Affect Unexpected Industries

14 Mar 23

Cannabis, News, Markets

Last week the US economy got clobbered by the biggest banking collapse since 2008 when the parent of Silicon Valley Bank, SVB Financial Group (NASDAQ: SIVB) failed to raise enough capital to continue.

Stocks That Hit 52-Week Lows On Friday

10 Mar 23

Options

On Friday, 497 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

8 Mar 23

Options

On Wednesday, 116 companies set new 52-week lows.

12 Health Care Stocks Moving In Monday's After-Market Session

6 Mar 23

Movers

Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights

15 May 23

Earnings, Press Releases

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 $44.4 million in cash and cash equivalents at March

Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference

12 Apr 23

Health Care, Press Releases

Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically significant and

Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference

5 Apr 23

News, Press Releases

DEVON, Pa., April 05, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders,

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

28 Mar 23

Earnings, Press Releases

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 European Commission granted orphan drug designation

Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank

13 Mar 23

Press Releases

DEVON, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders,

Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference

1 Mar 23

News, Press Releases

DEVON, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders,